{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"PFS at 2 years"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}],"title":"PFS at 1 year"}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"description":"Progression free survival (PFS) is defined for all subjects as the time from the date of initiation of treatment to the date of first documentation of relapse, progression, or death due to any cause. Full restaging was performed at 6, 12, 18, 24, 36, 48, 60, 72 months). PFS survival will be estimated and plotted with the Kaplan-Meier method. The median will be calculated with 95% confidence intervals.","groups":[{"description":"Lenalidomide Induction (with Low Dose Dexamethasone) Therapy Followed by Low Dose Melphalan, Prednisone, Lenalidomide and Bortezomib Sequential Maintenance Therapy\n\nLenalidomide Induction: Induction: Lenalidomide 25 mg daily on Days 1-21 followed by 7 day rest and Dexamethasone 40 mg by mouth (po) daily on Days 1, 8, 15 and 22 every 28 days for 4 cycles.\n\nSequential Maintenance Therapy: Subjects who achieve \\>partial response (PR) following induction therapy will receive repeating triplet cycles of alternating low dose therapy until progression, poor tolerance or toxicity. Subjects who complete 24 months of maintenance will be removed from study unless they achieved \\> stable disease (SD) from maintenance (per discussion with physician):\n\n* 325 mg aspirin for deep vein thrombosis (DVT) prophylaxis\n* Cycle 1, 4, 7, etc. - bortezomib 1.3 mg/m2 on day 1 and 8 of a 28-day cycle\n* Cycle 2, 5, 8 etc. - Melphalan 6 mg/m2 by mouth (po) daily on Days 1-7\n* Prednisone 60 mg /m2 po daily on","id":"OG000","title":"High-risk Multiple Myeloma"}],"paramType":"NUMBER","populationDescription":"Subjects enrolled and able to initiate induction therapy.","reportingStatus":"POSTED","timeFrame":"2 years","title":"Progression Free Survival","type":"PRIMARY","unitOfMeasure":"participants"}